Introduction:
The article discusses the potential of VHH antibodies, derived from camelids, to revolutionize the oral delivery of biologics. Traditional IgG monoclonal antibodies face challenges in oral therapies due to their large size and susceptibility to gastrointestinal degradation. In contrast, VHH antibodies offer smaller, modular antibody domains that are more stable and resistant to extreme conditions.
- Traditional IgG monoclonal antibodies degrade in harsh conditions of the gastrointestinal tract, hindering their oral administration.
- The large size of IgG antibodies hinders their absorption through the intestinal barrier, limiting their efficacy.
- VHH antibodies, with their small size, are more resistant to degradation and can be better absorbed through the intestinal lining.
- VHH antibodies can be engineered to enhance stability and flexibility, making them ideal candidates for oral therapeutic applications.
- VHH antibodies offer higher bioavailability and efficacy as oral medications compared to IgG antibodies.
Conclusion:
VHH antibodies represent a promising solution for the oral delivery of biologics. Their smaller size, stability, and flexibility make them more suitable for oral administration compared to traditional IgG antibodies. Clinical trials have shown promising results, indicating improved patient outcomes without invasive administration methods. The continued exploration and adaptation of VHH antibodies could revolutionize the field of oral antibody therapies and enhance the accessibility and efficiency of biologic treatments.
